Does Retatrutide Cause Diarrhea?
Yes, retatrutide causes diarrhea as one of its most common gastrointestinal side effects, occurring in a dose-dependent manner alongside nausea and vomiting. 1, 2, 3
Evidence from Clinical Trials
The clinical trial data consistently demonstrates that gastrointestinal adverse events, including diarrhea, are the most frequently reported side effects with retatrutide across all studied populations:
Obesity Trials
In the phase 2 obesity trial, gastrointestinal adverse events (nausea, diarrhea, vomiting) were the most common side effects reported across all retatrutide dose groups (1 mg to 12 mg) 3. These events were:
- Dose-related in frequency and severity
- Mostly mild to moderate in intensity
- Partially mitigated when using a lower starting dose (2 mg vs. 4 mg initial dose)
Type 2 Diabetes Trials
In participants with type 2 diabetes, mild-to-moderate gastrointestinal adverse events, including diarrhea, were reported in 35% of retatrutide-treated participants (ranging from 13% in the 0.5 mg group to 50% in the 8 mg fast escalation group), compared to 13% with placebo 2. The most recent phase 3 trial (TRANSCEND-T2D-1) confirmed that gastrointestinal events were the most frequent adverse events with retatrutide, though they generally subsided over time 4.
Clinical Context and Mechanism
This gastrointestinal side effect profile is entirely consistent with GLP-1 receptor agonist activity, which is a core component of retatrutide's triple-agonist mechanism (GLP-1, GIP, and glucagon receptors) 1, 2, 5. The diarrhea observed with retatrutide is comparable to that seen with other incretin-based therapies like semaglutide and tirzepatide 6.
Management Implications
The diarrhea associated with retatrutide is generally self-limiting and does not typically require treatment discontinuation. Study discontinuation rates due to adverse events were only 2-5% with retatrutide versus 0% with placebo 4. The systematic review of retatrutide trials confirmed that while gastrointestinal adverse effects were most commonly reported, they did not prevent the majority of participants from completing treatment 7.
Practical Mitigation Strategies:
- Start with lower initial doses (2 mg rather than 4 mg) to reduce gastrointestinal burden
- Titrate slowly to allow tolerance development
- Counsel patients that these symptoms typically improve over time
- Monitor for severity - most cases are mild to moderate and transient
Important caveat: The provided evidence does not address retatrutide-specific management protocols for diarrhea. Standard supportive care measures for medication-induced diarrhea would apply, though the cancer treatment-induced diarrhea guidelines 8, 9, 8, 9, 8, 9, 8, 9 are not directly applicable to this metabolic medication context.